Skip to main content
Premium Trial:

Request an Annual Quote

Amnis and Tripos and NovaScreen


Amnis Installs Cell Analysis Systems at Company, Academic, and Government Labs

Seattle-based Amnis said last week that it had recently installed its flagship technology, the ImageStream 100 Cell Analysis system, at three institutions as it prepares for a full commercial launch of the product next month.

The new ImageStream customers are Cell Therapeutics, the Fred Hutchinson Cancer Research Center, and the National Institute of Allergy and Infectious Disease. It had previously announced an installation at the Coriell Institute for Medical Research.

Amnis said that these biomedical research institutions had completed the early-access stage of the company’s commercialization process, which was designed to validate the system and provide feedback for the final commercial model.

The ImageStream is a fully automated instrument that combines laser-based microscopy with flow cytometry. The company said it is marketing the instrument as a tool for basic cell biology research, drug screening, and diagnostic applications.

Tripos, NovaScreen pen Drug-Discovery Collaboration for Strida Pharma

Tripos and NovaScreen announced last week that they have formed a collaboration to provide drug discovery services to Canadian pharmaceutical company Strida Pharma and its cancer therapeutics program.

Under the terms of the agreement, which was originally forged in August, Tripos will provide its “knowledge-driven chemistry expertise” with NovaScreen’s assay development and biological screening capabilities, according to a statement.

Tripos will identify, design, and synthesize compounds or biological activity assessment in a high-throughput methylenetetrahydrofolate reductase assay developed by NovaScreen, the companies said. The companies will then work together to develop primary screening hits to potential lead compounds.

Financial terms of the agreement were not disclosed.